Physician profile
Yeeck S Sim
NPI 1437595048
$38,222.61
in general payments reported to CMS, 2019-2025
44 companies · $2,777 in 2025
The $2,777 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.97 · 2020: $54.14 · 2021: $175 · 2022: $21K · 2023: $10K · 2024: $4,124 · 2025: $2,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $12K · Food and Beverage: $3,910 · Travel and Lodging: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $12,062.50 |
| Food and Beverage | $3,910.43 |
| Travel and Lodging | $1,175.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $34,382.96 | 2021-2025 | Xcopri |
| Abbvie INC. | $582.10 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Ucb, INC. | $475.56 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Jazz Pharmaceuticals INC. | $316.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $240.63 | 2022-2025 | |
| Emd Serono, INC. | $203.09 | 2023-2025 | Mavenclad |
| Immedica Pharma US, INC. | $150.00 | 2023 | |
| Eisai INC. | $130.84 | 2020-2025 | |
| Horizon Therapeutics Plc | $121.83 | 2022 | |
| Biogen, INC. | $114.30 | 2021-2025 | Tysabri |
| Sunovion Pharmaceuticals INC. | $109.25 | 2021-2022 | |
| Neurelis, INC. | $105.77 | 2023-2025 | Valtoco |
| Vanda Pharmaceuticals INC. | $97.47 | 2024-2025 | Ponvory |
| Catalyst Pharmaceuticals, INC. | $95.76 | 2023-2025 | Fycompa |
| Argenx US, INC. | $93.83 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75.61 | 2024-2025 | Uplizna |
| Pfizer INC. | $75.10 | 2023-2025 | |
| Lilly USA, LLC | $58.01 | 2022-2025 | Kisunla |
| Supernus Pharmaceuticals, INC. | $56.42 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $52.03 | 2025 | |
| Neuropace, INC. | $47.63 | 2024 | |
| Genzyme Corporation | $47.55 | 2025 | |
| Sumitomo Pharma America, INC. | $41.33 | 2023 | Aptiom |
| Axsome Therapeutics, INC. | $41.29 | 2025 | Sunosi |
| Tg Therapeutics, INC. | $40.75 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $40.12 | 2023 | Ongentys, Ingrezza |
| Mallinckrodt Hospital Products INC. | $39.74 | 2025 | Acthar |
| Impel Pharmaceuticals INC. | $39.25 | 2023 | Trudhesa |
| Csl Behring | $38.27 | 2025 | Hizentra |
| Alexion Pharmaceuticals, INC. | $32.93 | 2023-2024 | Ultomiris, Soliris |
| Celgene Corporation | $28.76 | 2025 | Zeposia |
| Merz Pharmaceuticals, LLC | $28.04 | 2025 | Inbrija, Xeomin, Ampyra |
| Genentech USA, INC. | $25.30 | 2023 | Ocrevus |
| Lundbeck LLC | $25.05 | 2025 | Vyepti |
| Cycle Pharmaceuticals INC | $23.83 | 2025 | Bafiertam, Tascenso Odt |
| Livanova USA, INC. | $22.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.39 | 2025 | Austedo Xr |
| Janssen Biotech, INC. | $19.30 | 2025 | |
| Tonix Medicines, INC. | $16.36 | 2025 | Zembrace Symtouch |
| Alnylam Pharmaceuticals INC. | $16.22 | 2024 | Amvuttra |
| Scilex Pharmaceuticals INC. | $15.80 | 2023 | Ztlido |
| Amneal Pharmaceuticals LLC | $15.49 | 2023 | Lyvispah |
| Allergan, INC. | $12.94 | 2021 | |
| Aucta Pharmaceuticals, INC. | $7.34 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yeeck Sim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.